| 臺大學術典藏 |
2022 |
Tolerability and efficacy of durvalumab, either as monotherapy or in combination with tremelimumab, in patients from Asia with advanced biliary tract, esophageal, or head-and-neck cancer
|
Doki Y.; Ueno M.; CHIH-HUNG HSU; Oh D.-Y.; Park K.; Yamamoto N.; Ioka T.; Hara H.; Hayama M.; Nii M.; Komuro K.; Sugimoto M.; Tahara M. |
| 臺大學術典藏 |
2021-03-09T06:46:02Z |
A randomized, open-label, Phase III clinical trial of nivolumab vs. therapy of investigator's choice in recurrent squamous cell carcinoma of the head and neck: A subanalysis of Asian patients versus the global population in checkmate 141
|
Kiyota N.;Hasegawa Y.;Takahashi S.;Yokota T.;Yen C.-J.;Iwae S.;Shimizu Y.;Ruey-Long Hong;Goto M.;Kang J.-H.;Sum Kenneth Li W.;Ferris R.L.;Gillison M.;Namba Y.;Monga M.;Lynch M.;Tahara M.; Kiyota N.; Hasegawa Y.; Takahashi S.; Yokota T.; Yen C.-J.; Iwae S.; Shimizu Y.; RUEY-LONG HONG; Goto M.; Kang J.-H.; Sum Kenneth Li W.; Ferris R.L.; Gillison M.; Namba Y.; Monga M.; Lynch M.; Tahara M. |
| 臺大學術典藏 |
2021-03-09T06:45:59Z |
Pembrolizumab alone or with chemotherapy versus cetuximab with chemotherapy for recurrent or metastatic squamous cell carcinoma of the head and neck (KEYNOTE-048): a randomised, open-label, phase 3 study
|
Burtness B.;Harrington K.J.;Greil R.;Souli?Res D.;Tahara M.;De Castro G.;Jr, Psyrri A.;Bast? N.;Neupane P.;Bratland ?.;Fuereder T.;Hughes B.G.M.;Mes?A R.;Ngamphaiboon N.;Rordorf T.;Wan Ishak W.Z.;Ruey-Long Hong;Gonz?Lez Mendoza R.;Roy A.;Zhang Y.;Gumuscu B.;Cheng J.D.;Jin F.;Rischin D.;Lerzo G.;Tatangelo M.;Varela M.;Zarba J.J.;Boyer M.;Gan H.;Gao B.;Hughes B.;Mallesara G.;Taylor A.;Burian M.;Barrios C.H.;De Castro Junior D.O.;Castro G.;Franke F.A.;Girotto G.;Lima I.P.F.;Nicolau U.R.;Pinto G.D.J.;Santos L.;Victorino A.-P.;Chua N.;Couture F.;Gregg R.;Hansen A.;Hilton J.;Mccarthy J.;Soulieres D.;Ascui R.;Gonzalez P.;Villanueva L.;Torregroza M.;Zambrano A.;Holeckova P.;Kral Z.;Melichar B.;Prausova J.;Vosmik M.;Andersen M.;Gyldenkerne N.;Jurgens H.;Putnik K.;Reinikainen P.;Gruenwald V.;Laban S.;Aravantinos G.;Boukovinas I.;Georgoulias V.;Kwong D.;Al-Farhat Y.;Csoszi T.;Erfan J.;Horvai G.;Landherr L.;Remenar E.;Ruzsa A.;Szota J.;Billan S.;Gluck I.;Gutfeld O.;Popovtzer A.;Benasso M.;Bui S.;Ferrari V.;Licitra L.;Nole F.;Fujii T.;Fujimoto Y.;Hanai N.;Hara H.;Matsumoto K.;Mitsugi K.;Monden N.;Nakayama M.;Okami K.;Oridate N.;Shiga K.;Shimizu Y.;Sugasawa M.;Takahashi M.;Takahashi S.;Tanaka K.;Ueda T.;Yamaguchi H.;Yamazaki T.;Yasumatsu R.;Yokota T.;Yoshizaki T.;Kudaba I.;Stara Z.;Cheah S.K.;Aguilar Ponce J.;Gonzalez Mendoza R.;Hernandez Hernandez C.;Medina Soto F.;Buter J.;Hoeben A.;Oosting S.;Suijkerbuijk K.;Bratland A.;Brydoey M.;Alvarez R.;Mas L.;Caguioa P.;Querol J.;Regala E.E.;Tamayo M.B.;Villegas E.M.;Kawecki A.;Karpenko A.;Klochikhin A.;Smolin A.;Zarubenkov O.;Goh B.C.;Cohen G.;Du Toit J.;Jordaan C.;Landers G.;Ruff P.;Szpak W.;Tabane N.;Brana I.;Iglesias Docampo L.;Lavernia J.;Mesia R.;Abel E.;Muratidu V.;Nielsen N.;Cristina V.;Rothschild S.;Wang H.-M.;Yang M.-H.;Yeh S.-P.;Yen C.-J.;Soparattanapaisarn N.;Sriuranpong V.;Aksoy S.;Cicin I.;Ekenel M.;Harputluoglu H.;Ozyilkan O.;Harrington K.;Agarwala S.;Ali H.;Alter R.;Anderson D.;Bruce J.;Campbell N.;Conde M.;Deeken J.;Edenfield W.;Feldman L.;Gaughan E.;Goueli B.;Halmos B.;Hegde U.;Hunis B.;Jotte R.;Karnad A.;Khan S.;Laudi N.;Laux D.;Martincic D.;Mccune S.;Mcgaughey D.;Misiukiewicz K.;Mulford D.;Nadler E.;Nunnink J.;Ohr J.;O'Malley M.;Patson B.;Paul D.;Popa E.;Powell S.;Redman R.;Rella V.;Rocha Lima C.;Sivapiragasam A.;Su Y.;Sukari A.;Wong S.;Yilmaz E.;Yorio J.; Burtness B.; Harrington K.J.; Greil R.; Souli?res D.; Tahara M.; de Castro G.; Jr, Psyrri A.; Bast? N.; Neupane P.; Bratland ?.; Fuereder T.; Hughes B.G.M.; Mes?a R.; Ngamphaiboon N.; Rordorf T.; Wan Ishak W.Z.; RUEY-LONG HONG; Gonz?lez Mendoza R.; Roy A.; Zhang Y.; Gumuscu B.; Cheng J.D.; Jin F.; Rischin D.; Lerzo G.; Tatangelo M.; Varela M.; Zarba J.J.; Boyer M.; Gan H.; Gao B.; Hughes B.; Mallesara G.; Taylor A.; Burian M.; Barrios C.H.; de Castro Junior D.O.; Castro G.; Franke F.A.; Girotto G.; Lima I.P.F.; Nicolau U.R.; Pinto G.D.J.; Santos L.; Victorino A.-P.; Chua N.; Couture F.; Gregg R.; Hansen A.; Hilton J.; McCarthy J.; Soulieres D.; Ascui R.; Gonzalez P.; Villanueva L.; Torregroza M.; Zambrano A.; Holeckova P.; Kral Z.; Melichar B.; Prausova J.; Vosmik M.; Andersen M.; Gyldenkerne N.; Jurgens H.; Putnik K.; Reinikainen P.; Gruenwald V.; Laban S.; Aravantinos G.; Boukovinas I.; Georgoulias V.; Kwong D.; Al-Farhat Y.; Csoszi T.; Erfan J.; Horvai G.; Landherr L.; Remenar E.; Ruzsa A.; Szota J.; Billan S.; Gluck I.; Gutfeld O.; Popovtzer A.; Benasso M.; Bui S.; Ferrari V.; Licitra L.; Nole F.; Fujii T.; Fujimoto Y.; Hanai N.; Hara H.; Matsumoto K.; Mitsugi K.; Monden N.; Nakayama M.; Okami K.; Oridate N.; Shiga K.; Shimizu Y.; Sugasawa M.; Takahashi M.; Takahashi S.; Tanaka K.; Ueda T.; Yamaguchi H.; Yamazaki T.; Yasumatsu R.; Yokota T.; Yoshizaki T.; Kudaba I.; Stara Z.; Cheah S.K.; Aguilar Ponce J.; Gonzalez Mendoza R.; Hernandez Hernandez C.; Medina Soto F.; Buter J.; Hoeben A.; Oosting S.; Suijkerbuijk K.; Bratland A.; Brydoey M.; Alvarez R.; Mas L.; Caguioa P.; Querol J.; Regala E.E.; Tamayo M.B.; Villegas E.M.; Kawecki A.; Karpenko A.; Klochikhin A.; Smolin A.; Zarubenkov O.; Goh B.C.; Cohen G.; du Toit J.; Jordaan C.; Landers G.; Ruff P.; Szpak W.; Tabane N.; Brana I.; Iglesias Docampo L.; Lavernia J.; Mesia R.; Abel E.; Muratidu V.; Nielsen N.; Cristina V.; Rothschild S.; Wang H.-M.; Yang M.-H.; Yeh S.-P.; Yen C.-J.; Soparattanapaisarn N.; Sriuranpong V.; Aksoy S.; Cicin I.; Ekenel M.; Harputluoglu H.; Ozyilkan O.; Harrington K.; Agarwala S.; Ali H.; Alter R.; Anderson D.; Bruce J.; Campbell N.; Conde M.; Deeken J.; Edenfield W.; Feldman L.; Gaughan E.; Goueli B.; Halmos B.; Hegde U.; Hunis B.; Jotte R.; Karnad A.; Khan S.; Laudi N.; Laux D.; Martincic D.; McCune S.; McGaughey D.; Misiukiewicz K.; Mulford D.; Nadler E.; Nunnink J.; Ohr J.; O'Malley M.; Patson B.; Paul D.; Popa E.; Powell S.; Redman R.; Rella V.; Rocha Lima C.; Sivapiragasam A.; Su Y.; Sukari A.; Wong S.; Yilmaz E.; Yorio J. |
| 臺大學術典藏 |
2021-03-09T06:45:59Z |
Two-year follow-up of a randomized phase III clinical trial of nivolumab vs. the investigator's choice of therapy in the Asian population for recurrent or metastatic squamous cell carcinoma of the head and neck (CheckMate 141)
|
Yen C.-J.; Kiyota N.; Hanai N.; Takahashi S.; Yokota T.; Iwae S.; Shimizu Y.; RUEY-LONG HONG; Goto M.; Kang J.-H.; Li W.S.K.; Ferris R.L.; Gillison M.; Endo T.; Jayaprakash V.; Tahara M. |
| 國立成功大學 |
2021 |
Palbociclib and cetuximab compared with placebo and cetuximab in platinum-resistant, cetuximab-na�ve, human papillomavirus-unrelated recurrent or metastatic head and neck squamous cell carcinoma: A double-blind, randomized, phase 2 trial
|
Adkins, D.R.;Lin, J.-C.;Sacco, A.;Ley, J.;Oppelt, P.;Vanchenko, Vanchenko V.;Komashko, N.;Yen, C.-J.;Wise-Draper, T.;Lopez-Picazo, Gonzalez J.;Radulovic, S.;Shen, Q.;Thurm, H.;Martini, J.-F.;Hoffman, J.;Huang, X.;Melichar, B.;Tahara, M. |
| 臺大學術典藏 |
2020-05-25T07:35:17Z |
Antitumor activity of pembrolizumab in biomarker-unselected patients with recurrent and/or metastatic head and neck squamous cell carcinoma: Results from the phase Ib KEYNOTE-012 expansion cohort
|
Seiwert T.Y.; Cheng J.D; Pathiraja K; Dolled-Filhart M; Meister A; Chung H.C; Chow L.Q.M; Haddad R; Gupta S; Mahipal A; Mehra R; Tahara M; Berger R; Eder J.P; Burtness B; Lee S.-H; Keam B; Kang H; Muro K; Weiss J; Geva R; Chia-Chi Lin |
| 臺大學術典藏 |
2020-05-25T07:35:12Z |
Pembrolizumab in Asia-Pacific patients with advanced head and neck squamous cell carcinoma: Analyses from KEYNOTE-012
|
Tahara M; Muro K; Hasegawa Y; Chung H.C; Chia-Chi Lin; Keam B; Takahashi K; Cheng J.D; Bang Y.-J. |
| 臺大學術典藏 |
2020-05-25T07:35:10Z |
Efficacy and safety of pembrolizumab in recurrent/metastatic head and neck squamous cell carcinoma: Pooled analyses after long-term follow-up in KEYNOTE-012
|
Cheng J; Chow L.Q.M; Haddad R.; Pathiraja K; Aurora-Garg D; Ray A; Chia-Chi Lin; Chung H.C; Geva R; Mehra R; Seiwert T.Y; Gupta S; Weiss J; Gluck I; Eder J.P; Burtness B; Tahara M; Keam B; Kang H; Muro K |
| 國立成功大學 |
2020 |
Two-year follow-up of a randomized phase III clinical trial of nivolumab vs. the investigator's choice of therapy in the Asian population for recurrent or metastatic squamous cell carcinoma of the head and neck (CheckMate 141)
|
Yen, C.-J.;Kiyota, N.;Hanai, N.;Takahashi, S.;Yokota, T.;Iwae, S.;Shimizu, Y.;Hong, R.-L.;Goto, M.;Kang, J.-H.;Li, W.S.K.;Ferris, R.L.;Gillison, M.;Endo, T.;Jayaprakash, V.;Tahara, M. |
| 國立成功大學 |
2015-12-01 |
Phase 3 trial of pembrolizumab as a first-line treatment in subjects with recurrent/metastatic head and neck squamous cell carcinoma: KEYNOTE-048
|
Yen, C. J.; Klochikhin, A.; Cohen, E.; Vermorken, J.; Harrington, K.; Tahara, M.; Ge, Y.; Geib, J.; Jin, F.; Burtness, B. |
